Evidence map›Paper›PMID 32224867›Full record

ArticlePolymers2020

GSK3787-Loaded Poly(Ester Amide) Particles for Intra-Articular Drug Delivery.

Ian J Villamagna, Danielle M McRae, Aneta Borecki, Xueli Mei, François Lagugné-Labarthet, Frank Beier, Elizabeth R Gillies

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Polymers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ian J VillamagnaSchool of Biomedical Engineering, The University of Western Ontario, London, ON N6A 5B9, Canada.
Danielle M McRaeDepartment of Chemistry, The University of Western Ontario, London, ON N6A 5B7, Canada.
Aneta BoreckiDepartment of Chemistry, The University of Western Ontario, London, ON N6A 5B7, Canada.
Xueli MeiDepartment of Chemistry, The University of Western Ontario, London, ON N6A 5B7, Canada.
François Lagugné-LabarthetBone and Joint Institute, The University of Western Ontario, London, ON N6A 5B9, Canada.ORCID 0000-0001-9882-9367
Frank BeierBone and Joint Institute, The University of Western Ontario, London, ON N6A 5B9, Canada.
Elizabeth R GilliesSchool of Biomedical Engineering, The University of Western Ontario, London, ON N6A 5B9, Canada.ORCID 0000-0002-3983-2248
Western University · CA

Funding

Natural Sciences and Engineering Research Council of Canada 2015-465675Natural Sciences and Engineering Research Council of Canada 2016-04636The Arthritis Society SOG-15-293
6 · The paper itself

Abstract

Osteoarthritis (OA) is a debilitating joint disorder affecting more than 240 million people. There is no disease modifying therapeutic, and drugs that are used to alleviate OA symptoms result in side effects. Recent research indicates that inhibition of peroxisome proliferator-activated receptor δ (PPARδ) in cartilage may attenuate the development or progression of OA. PPARδ antagonists such as GSK3787 exist, but would benefit from delivery to joints to avoid side effects. Described here is the loading of GSK3787 into poly(ester amide) (PEA) particles. The particles contained 8 wt.% drug and had mean diameters of about 600 nm. Differential scanning calorimetry indicated the drug was in crystalline domains in the particles. Atomic force microscopy was used to measure the Young's moduli of individual particles as 2.8 MPa. In vitro drug release studies showed 11% GSK3787 was released over 30 days. Studies in immature murine articular cartilage (IMAC) cells indicated low toxicity from the drug, empty particles, and drug-loaded particles and that the particles were not taken up by the cells. Ex vivo studies on murine joints showed that the particles could be injected into the joint space and resided there for at least 7 days. Overall, these results indicate that GSK3787-loaded PEA particles warrant further investigation as a delivery system for potential OA therapy.

Indexed as

atomic force microscopydrug deliveryGSK3787osteoarthritisparticlespoly(ester amide)

Identifiers

PMID32224867
PMCPMC7240550
OpenAlexW3013446319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.